Forced to Act: Omnitrope and the Battle for an FDA Commissioner
Generic biologics was not a priority for Andrew von Eschenbach when he accepted the job as acting commissioner of FDA. But two events -- a federal court ruling requiring a decision on Sandoz' Omnitrope NDA and the European Union approval of the follow-on biologic -- mean FDA may be pressed to take action on a regulatory pathway. The Omnitrope ruling makes it more important than ever that FDA have a fully confirmed leader in place, but it will also make it harder to get one.
You may also be interested in...
The pharmaceutical industry and FDA are getting ready for a fight-and for once they are on the same side. They want Congress to reauthorize the Prescription Drug User Fee Act quickly and cleanly-without tacking on other reforms to FDA's drug regulations. They probably won't get their wish.
FDA Commissioner Andrew von Eschenbach is poised to remain head of the agency, either in an acting role or as the White House nominee, through the end of the second Bush term. Other candidates were interviewed-including drug safety expert Ray Woosley, MD, but the administration appears to be happy with the job the National Cancer Institute Director is doing.
FDA wants to reverse the deline in NDA approvals; the agency may have a key ally at a new center in Arizona.